

### REMARKS

With the addition of claims 6-8, claims 1-8 are pending.

Descriptive support for the new claims 6-8 can be found in the specification at page 1, lines 6-8 and page 8, lines 1-5.

The amendments to claims 1, 3 and 4 are editorial and would not narrow the scope of the amended claim recitations.

Claim 5 is amended to correct its dependency. Claim 5, as filed, erroneously was made dependent on itself. Since a claim cannot depend on itself, it would have been apparent to a person skilled in the art that claim 5, as filed, was intended to depend on claim 4 because claim 4 was the only pharmaceutical composition claim before claim 5. Applicants submit that the correction of the claim dependency of claim 5 would not narrow the scope of the amended claim recitation.


Claims 6-8 are directed to certain embodiments of the present invention in a method format that correspond to the Swiss-type use claims 1-3.

The Examiner is invited to contact the undersigned at 202-220-4200 to discuss any matter in connection with this application.

The Office is hereby authorized to charge any fees under 37 C.F.R. 1.16 and 1.17 to the Kenyon & Kenyon Deposit Account No. 11-0600.

Respectfully submitted,

Dated: June 19, 2006

  
King L. Wong  
(Reg. No. 37,500)

KENYON & KENYON LLP  
1500 K Street, N.W., Suite 700  
Washington, DC 20005-1257  
Tel: (202) 220-4200  
Fax: (202) 220-4201